Cancer Research and Treatment

Comparative Evaluation of Safety and Efficacy of Alternate Schedule (AS) of Sunitinib in Asian and Non-Asian Patient Population for the Treatment of Metastatic Renal Cell Cancer (mRCC): A Meta-Analysis

Amit Joshi, Ishan Patel, Pratiksha Kapse, Manmohan Singh

High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma

Yun Beom Sang, Hannah Yang, Won Suk Lee, Seung Joon Lee, Seul-Gi Kim, Jaekyung Cheon, Beodeul Kang, Chang Woo Kim, Hong Jae Chon, Chan Kim

Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma

Dongrul Shin, Chang Wook Jeong, Cheryn Song, Minyong Kang, Seong Il Seo, Jung Kwon Kim, Hakmin Lee, Jinsoo Chung, Sung-Hoo Hong, Eu Chang Hwang, Cheol Kwak, Jae Young Park

Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population

Ahmed Badran, Mahmoud A. Elshenawy, Amgad Shahin, Ali Aljubran, Ahmed Alzahrani, Abdelmoneim Eldali, Shouki Bazarbashi

Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101

Motohide Uemura, Yoshihiko Tomita, Hideaki Miyake, Shingo Hatakeyama, Hiro‐omi Kanayama, Kazuyuki Numakura, Toshio Takagi, Tomoyuki Kato, Masatoshi Eto, Wataru Obara, Hirotsugu Uemura, Toni K. Choueiri, Robert J. Motzer, Yosuke Fujii, Yoichi Kamei, Yoshik

First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data

Xinan Sheng, Feng Bi, Xiubao Ren, Ying Cheng, Jinwan Wang, Brad Rosbrook, Ming Jiang, Jun Guo

The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics

Risk of fatal adverse events in cancer patients treated with sunitinib

Critical Reviews in Oncology/Hematology.2019; 137: 115. CrossRef

Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma

Jii Bum Lee, Hyung Soon Park, Sejung Park, Hyo Jin Lee, Kyung A Kwon, Young Jin Choi, Yu Jung Kim, Chung Mo Nam, Nam Hoon Cho, Beodeul Kang, Hyun Cheol Chung, Sun Young Rha

Cancer Research and Treatment.2019; 51(4): 1578. CrossRef

Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients

Claudia Arena, Giuseppe Troiano, Alfredo De Lillo, Nunzio F. Testa, Lorenzo Lo Muzio

BioMed Research International.2018; 2018: 1. CrossRef

Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma

Nahjatul Kursyiah Abd Ghafar, Adlinda Alip, Teng Aik Ong, Ning Yi Yap, Marniza Saad

Journal of Cancer Research and Therapeutics.2018; 14(6): 1303. CrossRef

Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis

Xiaoyan Liu, Marta Fiocco, Jesse J. Swen, Henk-Jan Guchelaar

Oncogenic miR-100-5p is associated with cellular viability, migration and apoptosis in renal cell carcinoma

Peijie Chen, Canbin Lin, Jing Quan, Yulin Lai, Tao He, Liang Zhou, Xiang Pan, Xueling Wu, Yong Wang, Liangchao Ni, Shangqi Yang, Tao Wang, Yongqing Lai

Molecular Medicine Reports.2017; 16(4): 5023. CrossRef

miR‑660‑5p is associated with cell migration, invasion, proliferation and apoptosis in renal cell carcinoma

Tao He, Peijie Chen, Lu Jin, Jia Hu, Yifan Li, Liang Zhou, Shangqi Yang, Xiangming Mao, Yaoting Gui, Yun Chen, Yongqing Lai

Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line Sunitinib Treatment in Advanced Renal Cell Carcinoma

Krisztián Nagyiványi, Barna Budai, Krisztina Bíró, Fruzsina Gyergyay, László Noszek, Zsófia Küronya, Hajnalka Németh, Péter Nagy, Lajos Géczi

Clinical Genitourinary Cancer.2016; 14(4): 314. CrossRef

BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen

Jung-woo Chae, Yi Ling Teo, Han Kiat Ho, Jaeyeon Lee, Hyun-moon Back, Hwi-yeol Yun, Mats O. Karlsson, Kwang-il Kwon, Alexandre Chan

Cancer Chemotherapy and Pharmacology.2016; 78(3): 623. CrossRef

Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study

Yoshihiko Tomita, Satoshi Fukasawa, Mototsugu Oya, Hirotsugu Uemura, Nobuo Shinohara, Tomonori Habuchi, Brian I. Rini, Ying Chen, Angel H. Bair, Seiichiro Ozono, Seiji Naito, Hideyuki Akaza

Japanese Journal of Clinical Oncology.2016; 46(11): 1031. CrossRef

Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction

Siew-Kee Low, Koya Fukunaga, Atsushi Takahashi, Koichi Matsuda, Fumiya Hongo, Hiroyuki Nakanishi, Hiroshi Kitamura, Takamitsu Inoue, Yoichiro Kato, Yoshihiko Tomita, Satoshi Fukasawa, Tomoaki Tanaka, Kazuo Nishimura, Hirotsugu Uemura, Isao Hara, Masato Fu

Sunitinib therapy for metastatic renal cell carcinoma: A urologist’s perspective

Journal of Clinical Urology.2016; 9(1): 32. CrossRef

Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience

Rafael Corrêa Coelho, Tomás Reinert, Franz Campos, Fábio Affonso Peixoto, Carlos Augusto de Andrade, Thalita Castro, Daniel Herchenhorn

International braz j urol.2016; 42(4): 694. CrossRef

Tumor suppressor miR-149-5p is associated with cellular migration, proliferation and apoptosis in renal cell carcinoma

LU JIN, YIFAN LI, JIAJU LIU, SHANGQI YANG, YAOTING GUI, XIANGMING MAO, GUOHUI NIE, YONGQING LAI

Molecular Medicine Reports.2016; 13(6): 5386. CrossRef

Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore

Hui Shan Tan, Huihua Li, Yu Wen Hong, Chee-Keong Toh, Alvin Wong, Gilberto Lopes, Miah Hiang Tay, Alexandre Chan, Xin Yao, Tiffany Tang, Quan Sing Ng, Ravindran Kanesvaran, Noan Minh Chau, Min-Han Tan

Clinical Genitourinary Cancer.2015; 13(4): e285. CrossRef

Central and Eastern European Experience with Sunitinib in Metastatic Renal Cell Carcinoma: A Sub-analysis of the Global Expanded-Access Trial

Eduard Vrdoljak, Lajos Géczi, Jozef Mardiak, Tudor-Eliade Ciuleanu, Sophie Leyman, Ke Zhang, Peter Sajben, Laszlo Torday

Pathology & Oncology Research.2015; 21(3): 775. CrossRef

Axitinib plasma pharmacokinetics and ethnic differences

Ying Chen, Akiyuki Suzuki, Michael A. Tortorici, May Garrett, Robert R. LaBadie, Yoshiko Umeyama, Yazdi K. Pithavala

Investigational New Drugs.2015; 33(2): 521. CrossRef

Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors

Pharmacology & Therapeutics.2015; 152: 125. CrossRef

RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial

J.L. Lee, M.K. Kim, I. Park, J.-H. Ahn, D.H. Lee, H.M. Ryoo, C. Song, B. Hong, J.H. Hong, H. Ahn

Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer

Naomi Kiyota, Martin Schlumberger, Kei Muro, Yuichi Ando, Shunji Takahashi, Yasukazu Kawai, Lori Wirth, Bruce Robinson, Steven Sherman, Takuya Suzuki, Katsuki Fujino, Anubha Gupta, Seiichi Hayato, Makoto Tahara

Efficacy and Toxicity of Sunitinib in Metastatic Renal Cell Carcinoma Patients in Egypt

Asian Pacific Journal of Cancer Prevention.2015; 16(5): 1971. CrossRef

Induction of apoptotic cell death by betulin in multidrug-resistant human renal carcinoma cells

NAM-HUI YIM, YOUNG PIL JUNG, AEYUNG KIM, TAESOO KIM, JIN YEUL MA

Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients

Y Wang, T K Choueiri, J-L Lee, M-H Tan, S Y Rha, S A North, C K Kollmannsberger, D F McDermott, D Y C Heng

British Journal of Cancer.2014; 110(6): 1433. CrossRef

The Effect of ABCG2 Genotype on the Population Pharmacokinetics of Sunitinib in Patients With Renal Cell Carcinoma

Tomoyuki Mizuno, Masahide Fukudo, Tsuyoshi Fukuda, Tomohiro Terada, Min Dong, Tomomi Kamba, Toshinari Yamasaki, Osamu Ogawa, Toshiya Katsura, Ken-ichi Inui, Alexander A. Vinks, Kazuo Matsubara

Therapeutic Drug Monitoring.2014; 36(3): 310. CrossRef

Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma

Ibrahim Yildiz, Fatma Sen, Leyla Kilic, Rumeysa Ciftci, Mert Basaran

Korean Journal of Urology.2014; 55(1): 74. CrossRef

Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first‐line sunitinib: a medical chart review across ten centers in five European countries

Camillo Porta, Antonin Levy, Robert Hawkins, Daniel Castellano, Joaquim Bellmunt, Paul Nathan, Ray McDermott, John Wagstaff, Paul Donnellan, John McCaffrey, Francis Vekeman, Maureen P. Neary, Jose Diaz, Faisal Mehmud, Mei Sheng Duh

Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review

WILLIAM K. OH, DAVID McDERMOTT, CAMILLO PORTA, ANTONIN LEVY, REZA ELAIDI, FLORIAN SCOTTE, ROBERT HAWKINS, DANIEL CASTELLANO, JOAQUIM BELLMUNT, SUN YOUNG RHA, JONG-MU SUN, PAUL NATHAN, BRUCE A. FEINBERG, JEFFREY SCOTT, RAY McDERMOTT, JIN-HEE AHN, JOHN WAGS

International Journal of Oncology.2014; 44(1): 5. CrossRef

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma

R J Motzer, B Escudier, R Bukowski, B I Rini, T E Hutson, C H Barrios, X Lin, K Fly, E Matczak, M E Gore

British Journal of Cancer.2013; 108(12): 2470. CrossRef

Therapy management with sunitinib in patients with metastatic renal cell carcinoma: Key concepts and the impact of clinical biomarkers

Daniel Castellano, Alain Ravaud, Manuela Schmidinger, Guillermo De Velasco, Federico Vazquez

Cancer Treatment Reviews.2013; 39(3): 230. CrossRef

Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients

Hye Ryun Kim, Hyung Soon Park, Woo Sun Kwon, Ji Hyun Lee, Yusuke Tanigawara, Sun Min Lim, Hyo Song Kim, Sang Jun Shin, Jung Bae Ahn, Sun Young Rha

Cancer Chemotherapy and Pharmacology.2013; 72(4): 825. CrossRef

Validation of the MSKCC and Heng Risk Criteria Models for Predicting Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib

Whi-An Kwon, In-Chang Cho, Ami Yu, Byung-Ho Nam, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung

Annals of Surgical Oncology.2013; 20(13): 4397. CrossRef

Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma

Ki Hyang Kim, Sang Hyun Yoon, Hae-Jung Lee, Hyo Song Kim, Sang Joon Shin, Joong Bae Ahn, Sun Young Rha

Cancer Chemotherapy and Pharmacology.2013; 72(4): 853. CrossRef

Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain

Daniel Castellano, Mei Sheng Duh, Caroline Korves, Ellison Dial Suthoff, Maureen Neary, Luis Javier Hernández Pastor, Joaquim Bellmunt

Expert Opinion on Drug Safety.2013; 12(4): 455. CrossRef

Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib

Aiping Zhou, Wen Zhang, Chunxiao Chang, Xiaoyan Chen, Dafang Zhong, Qiong Qin, Donghua Lou, Haoyuan Jiang, Jinwan Wang

Cancer Chemotherapy and Pharmacology.2013; 72(5): 1043. CrossRef

Analysis of the Reasons for Dose Reduction or Discontinuation of Sunitinib in Korean Patients

노지혜, 이주연, 이혜숙, 김향숙, 강래영, 이용화

Journal of Korean Society of Health-System Pharmacists.2013; 30(3): 210. CrossRef

Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Pharmacokinetics of Sunitinib in Rats

Sachiko Kunimatsu, Tomoyuki Mizuno, Masahide Fukudo, Toshiya Katsura

Drug Metabolism and Disposition.2013; 41(8): 1592. CrossRef

Famitinib in metastatic renal cell carcinoma: a single center study

Wen ZHANG, Ai-Ping ZHOU, Qiong QIN, Chun-Xiao CHANG, Hao-Yuan JIANG, Jian-Hui MA, Jin-Wan WANG

Chinese Medical Journal.2013; 126(22): 4277. CrossRef

Management of sunitinib adverse events in renal cell carcinoma patients: The Asian experience

Asia-Pacific Journal of Clinical Oncology.2012; 8(2): 132. CrossRef

Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients

Dok Hyun Yoon, Min-Hee Ryu, Baek-Yeol Ryoo, Moyeol Beck, Dae Ro Choi, Yoojin Cho, Jae-Lyun Lee, Heung-Moon Chang, Tae Won Kim, Yoon-Koo Kang

Investigational New Drugs.2012; 30(2): 819. CrossRef

Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma

Korean Journal of Urology.2012; 53(4): 217. CrossRef

Impact of Genetic Variation in Breast Cancer Resistance Protein (BCRP/ABCG2) on Sunitinib Pharmacokinetics

Tomoyuki Mizuno, Masahide Fukudo, Tomohiro Terada, Tomomi Kamba, Eijiro Nakamura, Osamu Ogawa, Ken-ichi Inui, Toshiya Katsura

Drug Metabolism and Pharmacokinetics.2012; 27(6): 631. CrossRef

Response Rates and Adverse Effects of Continuous Once-daily Sunitinib in Patients with Advanced Renal Cell Carcinoma: A Single-center Study in Turkey

I. Yildiz, F. Sen, M. Basaran, M. Ekenel, F. Agaoglu, E. Darendeliler, H. M. Tunc, F. Ozcan, S. Bavbek

Japanese Journal of Clinical Oncology.2011; 41(12): 1380. CrossRef

Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma

Yoshihiko Tomita, Hirotsugu Uemura, Hiroyuki Fujimoto, Hiro-omi Kanayama, Nobuo Shinohara, Hayakazu Nakazawa, Keiji Imai, Yoshiko Umeyama, Seiichiro Ozono, Seiji Naito, Hideyuki Akaza

European Journal of Cancer.2011; 47(17): 2592. CrossRef

Efficacy and Safety of Sunitinib on Metastatic Renal Cell Carcinoma: A Single-Institution Experience

Eugene Hwang, Hyo Jin Lee, Chong Koo Sul, Jae Sung Lim

Korean Journal of Urology.2010; 51(7): 450. CrossRef

S. Naito, Y. Tomita, S. Y. Rha, H. Uemura, M. Oya, H. Z. Song, L. H. Zhong, M. I. B. A. Wahid

Japanese Journal of Clinical Oncology.2010; 40(Supplement): i51. CrossRef

Hematologic Toxicity in Patients Treated with Sunitinib for Advanced Thyroid Cancer

Anastasios Gkountouvas, Ifigeneia Kostoglou-Athanassiou, Eirini Veniou, Panagiotis Repousis, Nikolaos Ziras, Philippos Kaldrimidis

The Efficacy and Safety of Sunitinib in Korean Patients with Advanced Renal Cell Carcinoma: High Incidence of Toxicity Leads to Frequent Dose Reduction

C. Yoo, J. E. Kim, J.-L. Lee, J.-H. Ahn, D. H. Lee, J.-S. Lee, S. Na, C.-S. Kim, J. H. Hong, B. Hong, C. Song, H. Ahn

Japanese Journal of Clinical Oncology.2010; 40(10): 980. CrossRef

Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis

Sang Hyun Yoon, Ki Hyang Kim, Junjeong Choi, Gun Min Kim, Joo Hoon Kim, Hyo Song Kim, Young Nyun Park, Sun Young Rha

Cancer Research and Treatment.2010; 42(3): 180. CrossRef

Comparative Analysis between Immunochemotherapy and Target Therapy for Metastatic Renal Cell Carcinoma: Overview of Treatment-Related Adverse Events and the Dropout Rate in Korea

Jee Han Lee, Sung-Goo Chang, Seung Hyun Jeon, Gyeong Eun Min, Koo Han Yoo

Korean Journal of Urology.2010; 51(6): 379. CrossRef